Conflict of Interest

It is the policy of The University of Texas MD Anderson Cancer Center (MD Anderson) that faculty members, trainees, faculty supervisors, institutional decision makers, and investigators must follow certain procedures in order to ensure the protection of patient safety and welfare, safeguard the reputation and integrity of the institution, and preserve the integrity of affiliated research, while permitting the pursuit of relationships with for-profit entities that further the mission of MD Anderson or that serve another scholarly purpose.

These procedures are outlined in MD Anderson's Conflict of Interest Policy for Faculty Members, Trainees, Faculty Supervisors, Institutional Decision Makers, and Investigators of The University of Texas MD Anderson Cancer Center (MD Anderson Institutional Policy #ACA0001). MD Anderson's Institutional Compliance Office administers this policy and, in conjunction with MD Anderson's Conflict of Interest Committee, reviews financial interest disclosures required by this policy.

As required by Public Health Service federal regulations regarding its grants or cooperative agreements, MD Anderson's Institutional Compliance Office makes available to the public: (1) the institution’s policy on conflicts of interest; as well as (2) information related to disclosed significant financial interest(s) that are determined by MD Anderson to be financial conflict of interest(s) for senior/key personnel working on a funded research project, including:

• the Investigator's name;
• the Investigator's title and role with respect to the research project;
• the name of the entity in which the significant financial interest is held;
• the nature of the significant financial interest; and
• the approximate dollar value of the significant financial interest.

View MD Anderson's Policy and Disclosures:

• Conflict of Interest Policy for Faculty Members, Trainees, Faculty Supervisors, Institutional Decision Makers, and Investigators of The University of Texas MD Anderson Cancer Center (MD Anderson Institutional Policy # ACA0001)
• A list of MD Anderson Determined Financial Conflict(s) of Interest for Senior/Key Personnel Working on a Research Project with an Award Date after August 23, 2012; updated May 20, 2024 (pdf)
• Institutional Conflict of Interest: ADC Therapeutics (pdf)
• Institutional Conflict of Interest: Affimed (pdf)
• Institutional Conflict of Interest: Artios (pdf)
• Institutional Conflict of Interest: BluePrint (pdf)
• Institutional Conflict of Interest: Boehringer Ingelheim (pdf)
• Institutional Conflict of Interest: BostonGene
• Institutional Conflict of Interest: BrainCheck (pdf)
• Institutional Conflict of Interest: Cellenkos Inc. (pdf)
• Institutional Conflict of Interest: Cell Therapy Manufacturing Center (CTMC) (pdf)
• Institutional Conflict of Interest: Codiak (pdf)
• Institutional Conflict of Interest: Convergent (pdf)
• Institutional Conflict of Interest: CureVac (pdf)
• Institutional Conflict of Interest: CV Biomanufacturing (pdf)
• Institutional Conflict of Interest: Eisbach (pdf)
• Institutional Conflict of Intrest: Empyrean (pdf)
• Institutional Conflict of Interest: Exscientia (pdf)
• Institutional Conflict of Interest: Generate Biomedicines (pdf)
• Institutional Conflict of Interest: Guardant (pdf)
• Institutional Conflict of Interest: Immatics (pdf)
• Institutional Conflict of Interest: ImmunoGenesis (pdf)
• Institutional Conflict of Interest: Innovent (pdf)
• Institutional Conflict of Interest: Invectys (pdf)
• Institutional Conflict of Interest: Ionis (pdf)
• Institutional Conflict of Interest: ISA(pdf)
• Institutional Conflict of Interest: KAHR (pdf)
• Institutional Conflict of Interest: Kallisio (pdf)
• Institutional Conflict of Interest: LeanTaaS (pdf)
• Institutional Conflict of Interest: Lixte (pdf)
• Institutional Conflict of Interest: Manaolana (pdf)
• Institutional Conflict of Interest: March Biosciences (pdf)
• Institutional Conflict of Interest: Mereo (pdf)
• Institutional Conflict of Interest: Moleculin (pdf)
  
• Institutional Conflict of Interest: Navire (pdf)
• Institutional Conflict of Interest: Nectin (pdf)
• Institutional Conflict of Interest: Novel Anti-Infective Technologies (pdf)
  
• Institutional Conflict of Interest: Obsidian (pdf)
• Institutional Conflicts of Interst: Oral Cladribine (pdf)
• Institutional Conflict of Interest: OmniNano (pdf)
• Institutional Conflict of Interest: Oncora (pdf)
• Institutional Conflict of Interest: Oncoceutics (pdf)
• Institutional Conflict of Interest: OncoResponse (pdf)
• Institutional Conflict of Interest: Osel (pdf)
• Institutional Conflict of Interest: RaySearch (pdf)
• Institutional Conflict of Interest: RadioPharm Ventures (pdf)
• Institutional Conflict of  Interest: Replay-Syena (pdf)
• Institutional Conflict of Interest: Sibylla (pdf)
• Institutional Conflict of Interest: Spectrum Pharmaceuticals (pdf)
• Institutional Conflict of Interest: Takeda (pdf)
• Institutional Conflict of Interest: Tvardi Therapeutics, Inc. (pdf)
• Institutional Conflict of Interest: Vescor Therapeutics, L.L.C. (pdf)
• Institutional Conflict of Interest: Xencor (pdf)
• Institutional Conflict of Interest: Ziopharm Oncology, Inc. (pdf)

If you have specific questions regarding the information made available, please contact MD Anderson’s Conflict of Interest team at COIC@mdanderson.org.

20240524 CPD